All In Biotech

Drug Trial Radar · NCT07519278

Bioequivalence Study of Pramipexole Dihydrochloride Extended-release Tablets in Healthy Chinese Subjects

Comparative Pharmacokinetics for Bioequivalence of Pramipexole Dihydrochloride Extended-Release Tablets in Fasting and Fed Chinese Healthy Volunteers: A Randomized, Open-label, Single-dose, Crossover Study

Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Mar 16, 2017

Primary completion

Apr 11, 2017

Study completion Feb 12, 2018

Sponsor

Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study compared pramipexole dihydrochloride extended-release tablets (Test formulation) by Haisco Pharmaceutical Group Co., Ltd. with the reference formulation (MIRAPEX ER®,Boehringer Ingelheim GmbH of Germany) to evaluate the bioequivalence of single dose in Chinese healthy subjects under fasting and fed conditions.

Conditions

  • Healthy

Interventions

  • Test formulation(pramipexole dihydrochloride extended-release tablets)Drug

    Test formulation (pramipexole dihydrochloride extended-release tablets, Haisco Pharmaceutical Group Co., Ltd), A single oral dose of 0.375 mg, taken with 240mL of water

  • Reference formulation(MIRAPEX ER®)Drug

    Reference formulation (pramipexole dihydrochloride extended-release tablets, Boehringer Ingelheim GmbH of Germany), A single oral dose of 0.375 mg, taken with 240mL of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax (Maximum Concentration)Time frame: From the start of administration to 72 hours post-dose
  2. AUC(0-t) (Area Under the Concentration-Time Curve from time 0 to time t)Time frame: From the start of administration to 72 hours post-dose
  3. AUC(0-∞) (Area Under the Concentration-Time Curve from time 0 to infinity)Time frame: From the start of administration to 72 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The General Hospital of Western Theater Command PLA

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.